Quantcast

Colorado BioScience Association welcomes new directors

Four life sciences leaders bring deep expertise to support CBSA members, as they join as new members of the Board of Directors.

DENVER–(BUSINESS WIRE)–#cobioscience–Colorado BioScience Association (CBSA) announces the appointment of four new members to the CBSA Board of Directors. Elyse Blazevich, Securisyn Medical Co-Founder, Chief Operating Officer and Chief Financial Officer; April Giles, Fitzsimons Innovation Community Vice President of Business Development; Joseph Guiles, Ph.D., Agilent Technologies, Inc. Head of Development; and Andrew Sklawer, Brickell Bio Co-Founder and Chief Operating Officer will serve three-year terms.

Selected for their experience leading high-growth organizations, developing partnerships and bringing life-saving products to market, the new board members are respected leaders in Colorado’s life sciences community.

Elyse Blazevich, Securisyn Medical Co-Founder, Chief Operating Officer and Chief Financial Officer: Creates and executes strategies for the company, which is dedicated to making airway management safer and focuses on eliminating unplanned extubation deaths.

April Giles, Fitzsimons Innovation Community Vice President of Business Development: Leads growth and partnership development for the leading innovation community, an entrepreneurial environment that offers specialized space and services for more than 70 companies and organizations.

Joseph Guiles, Ph.D., Agilent Technologies, Inc. Head of Development: Leads technical development teams at Agilent’s facilities in Boulder and Frederick, Colo., which specialize in supplying nucleic acid-based therapeutics to pharmaceutical and biotech company’s worldwide. Agilent’s corporate focus is to provide life sciences, diagnostics and applied chemical markets with instruments, services, consumables, applications and expertise.

Andrew Sklawer, Brickell Bio Co-Founder and Chief Operating Officer: Leads operations for the clinical-stage pharmaceutical company, which focuses on developing innovative and differentiated prescription therapeutics for treatment of skin diseases.

Jennifer Jones Paton, President and CEO of CBSA said:

“Our newest board members represent companies and organizations at all stages of innovation. They understand the support and leadership our life sciences ecosystem needs for success. We’re pleased to welcome leaders from Securisyn Medical, Fitzsimons Innovation Community, Agilent Technologies and Brickell Bio to the Colorado BioScience Association Board of Directors.”

The 29-person CBSA Board of Directors is comprised of representatives from the state’s biotechnology, medical device, diagnostic, pharmaceutical, ag bio, digital health, healthcare, and research organizations.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.